Cabozantinib (XL184) is a potent, orally active VEGFR2 and MET inhibitor (IC50 = 0.035 and 1.3 nM, respectively) with additional activity against KIT, RET, AXL, TIE2, and FLT3, exhibiting antiangiogenic and pro-apoptotic effects in tumors. Reagent grade, for research purpose.
Usually ships within 24 hours.